Burning mouth syndrome responsive to pramipexol

Burning mouth syndrome (BMS) is characterized by burning discomfort or pain in otherwise normal oral mucosa. It is usually refractory. Treatment modalities are scarce. Herein we report one case of primary disabling BMS, previously refractory to multiple regimens, with complete and persistent improve...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of headache and pain 2008-02, Vol.9 (1), p.43-45
Hauptverfasser:	Stuginski-Barbosa, J., Rodrigues, G. G. R., Bigal, M. E., Speciali, J. G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Benzothiazoles - administration & dosage Biological and medical sciences Brief Report Burning Mouth Syndrome - drug therapy Burning Mouth Syndrome - metabolism Burning Mouth Syndrome - physiopathology Burns Corpus Striatum - drug effects Corpus Striatum - metabolism Corpus Striatum - physiopathology Diseases of striated muscles. Neuromuscular diseases Dopamine - metabolism Dopamine Agonists - administration & dosage Dose-Response Relationship, Drug Drug Administration Schedule Drug Resistance - drug effects Drug Resistance - physiology Drug therapy Female Humans Internal Medicine Medical disorders Medical sciences Medicine Medicine & Public Health Mouth Mouth Mucosa - drug effects Mouth Mucosa - innervation Mouth Mucosa - physiopathology Neurology Neurons Pain Medicine Parkinson Disease - complications Parkinson Disease - drug therapy Parkinson Disease - physiopathology Pramipexole Prospective Studies Receptors, Dopamine D2 - agonists Receptors, Dopamine D2 - metabolism Restless Legs Syndrome - drug therapy Restless Legs Syndrome - physiopathology Substance Withdrawal Syndrome - physiopathology Traumas. Diseases due to physical agents Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Burning mouth syndrome (BMS) is characterized by burning discomfort or pain in otherwise normal oral mucosa. It is usually refractory. Treatment modalities are scarce. Herein we report one case of primary disabling BMS, previously refractory to multiple regimens, with complete and persistent improvement with pramipexol, a nonergot dopamine agonist which has high selectivity for dopaminergic D2 receptors. We discuss potential pathophysiological implications of our findings.
ISSN:	1129-2369 1129-2377
DOI:	10.1007/s10194-008-0003-4